299 related articles for article (PubMed ID: 31117037)
1. New Therapies for Ovarian Cancer.
O'Malley DM
J Natl Compr Canc Netw; 2019 May; 17(5.5):619-621. PubMed ID: 31117037
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.
Walsh C
Minerva Ginecol; 2018 Apr; 70(2):150-170. PubMed ID: 28994564
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
Gupta S; Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2019 Nov; 12(1):103. PubMed ID: 31685032
[TBL] [Abstract][Full Text] [Related]
4. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
5. PARP Inhibitors in Ovarian Cancer.
Mittica G; Ghisoni E; Giannone G; Genta S; Aglietta M; Sapino A; Valabrega G
Recent Pat Anticancer Drug Discov; 2018; 13(4):392-410. PubMed ID: 29512470
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors in ovarian cancer.
Ledermann JA
Ann Oncol; 2016 Apr; 27 Suppl 1():i40-i44. PubMed ID: 27141070
[TBL] [Abstract][Full Text] [Related]
7. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
Armstrong DK; Alvarez RD; Bakkum-Gamez JN; Barroilhet L; Behbakht K; Berchuck A; Berek JS; Chen LM; Cristea M; DeRosa M; ElNaggar AC; Gershenson DM; Gray HJ; Hakam A; Jain A; Johnston C; Leath CA; Liu J; Mahdi H; Matei D; McHale M; McLean K; O'Malley DM; Penson RT; Percac-Lima S; Ratner E; Remmenga SW; Sabbatini P; Werner TL; Zsiros E; Burns JL; Engh AM
J Natl Compr Canc Netw; 2019 Aug; 17(8):896-909. PubMed ID: 31390583
[TBL] [Abstract][Full Text] [Related]
8. Management of newly diagnosed or recurrent ovarian cancer.
Matulonis UA
Clin Adv Hematol Oncol; 2018 Jun; 16(6):426-437. PubMed ID: 30067614
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
10. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
11. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
[No Abstract] [Full Text] [Related]
12. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
13. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
15. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; In the light of completed trials.
Korkmaz T; Seber S; Basaran G
Crit Rev Oncol Hematol; 2016 Feb; 98():180-8. PubMed ID: 26603345
[TBL] [Abstract][Full Text] [Related]
16. [Position of targeted therapy in ovarian cancer management].
Majirský M; Kubecová M; Kindlová E; Tikovský K
Ceska Gynekol; 2013 Aug; 78(4):347-50. PubMed ID: 24040982
[TBL] [Abstract][Full Text] [Related]
17. New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances.
Liu J; Matulonis UA
Clin Cancer Res; 2014 Oct; 20(20):5150-6. PubMed ID: 25320365
[TBL] [Abstract][Full Text] [Related]
18. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
19. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Mirza MR; Pignata S; Ledermann JA
Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
[TBL] [Abstract][Full Text] [Related]
20. [Innovations in the treatment of ovarian cancer. Analysis of the therapeutic development: from platinum to immunotherapy.].
Angius G; Sepe P; Papa A; Tomao S; Tomao F
Recenti Prog Med; 2017 Jun; 108(6):269-281. PubMed ID: 28631775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
